ID30064A - Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion - Google Patents

Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Info

Publication number
ID30064A
ID30064A IDW00200101331A ID20011331A ID30064A ID 30064 A ID30064 A ID 30064A ID W00200101331 A IDW00200101331 A ID W00200101331A ID 20011331 A ID20011331 A ID 20011331A ID 30064 A ID30064 A ID 30064A
Authority
ID
Indonesia
Prior art keywords
crystal
methyl
tiazolidinedion
fluorobenzil
oksi
Prior art date
Application number
IDW00200101331A
Other languages
English (en)
Indonesian (id)
Inventor
Takayuki Oe
Hiroaki Ueno
Akira Maruyama
Katsuhiko Masuda
Original Assignee
Mitsibishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsibishi Chemical Corp filed Critical Mitsibishi Chemical Corp
Publication of ID30064A publication Critical patent/ID30064A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IDW00200101331A 1998-11-20 1999-11-19 Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion ID30064A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20

Publications (1)

Publication Number Publication Date
ID30064A true ID30064A (id) 2001-11-01

Family

ID=18233859

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101331A ID30064A (id) 1998-11-20 1999-11-19 Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Country Status (23)

Country Link
US (3) US6541493B1 (ko)
EP (1) EP1131310B1 (ko)
JP (1) JP3784001B2 (ko)
KR (1) KR100652326B1 (ko)
CN (1) CN1326449A (ko)
AT (1) ATE315552T1 (ko)
AU (1) AU1185100A (ko)
BR (1) BR9916795A (ko)
CA (1) CA2351727C (ko)
CZ (1) CZ20011763A3 (ko)
DE (1) DE69929476T2 (ko)
ES (1) ES2257104T3 (ko)
HU (1) HUP0104139A3 (ko)
ID (1) ID30064A (ko)
IL (1) IL143177A0 (ko)
NO (1) NO20012444L (ko)
NZ (1) NZ512429A (ko)
PL (1) PL348502A1 (ko)
PT (1) PT1131310E (ko)
TR (4) TR200202110T2 (ko)
TW (2) TWI250156B (ko)
WO (1) WO2000031055A1 (ko)
ZA (1) ZA200104081B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL348502A1 (en) * 1998-11-20 2002-05-20 Mitsubishi Chem Corp Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione
WO2001036401A1 (en) * 1999-11-19 2001-05-25 Ortho-Mcneil Pharmaceutical, Inc. Solid state forms of 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
BRPI0907463A2 (pt) * 2008-02-04 2019-09-24 Pfizer Ltd forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
PL348502A1 (en) * 1998-11-20 2002-05-20 Mitsubishi Chem Corp Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione

Also Published As

Publication number Publication date
DE69929476D1 (de) 2006-04-06
TWI272944B (en) 2007-02-11
TR200202110T2 (tr) 2002-10-21
ES2257104T3 (es) 2006-07-16
BR9916795A (pt) 2002-04-09
JP3784001B2 (ja) 2006-06-07
TW200613291A (en) 2006-05-01
TR200101901T2 (tr) 2002-04-22
CZ20011763A3 (cs) 2001-10-17
EP1131310A1 (en) 2001-09-12
CA2351727C (en) 2008-09-23
KR100652326B1 (ko) 2006-11-29
NZ512429A (en) 2003-11-28
NO20012444L (no) 2001-07-18
JP2002530392A (ja) 2002-09-17
EP1131310B1 (en) 2006-01-11
WO2000031055A1 (en) 2000-06-02
HUP0104139A2 (hu) 2002-03-28
KR20010101033A (ko) 2001-11-14
ZA200104081B (en) 2002-05-20
IL143177A0 (en) 2002-04-21
HUP0104139A3 (en) 2003-12-29
US20060149075A1 (en) 2006-07-06
CA2351727A1 (en) 2000-06-02
TR200202109T2 (tr) 2002-11-21
DE69929476T2 (de) 2006-09-14
AU1185100A (en) 2000-06-13
NO20012444D0 (no) 2001-05-18
PL348502A1 (en) 2002-05-20
CN1326449A (zh) 2001-12-12
TR200202103T2 (tr) 2002-11-21
ATE315552T1 (de) 2006-02-15
TWI250156B (en) 2006-03-01
US6541493B1 (en) 2003-04-01
US20030158241A1 (en) 2003-08-21
PT1131310E (pt) 2006-05-31

Similar Documents

Publication Publication Date Title
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
BG103268A (en) Propionic acid derivatives and their application
KR970704687A (ko) 무스카린성 수용체에서 알로스테릭 효과기로서 유용한 헤테로고리 화합물(heterocyclic compounds, useful as allosteric effectors at muscarinic receptors)
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
IE831085L (en) Terahydroquinoline derivatives and their 'o' and 's'¹analogues
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
CA2130174A1 (en) 4-oxo-2 thioxoimidazolidine derivatives as inhibitors of blood platelet aggregation
EA200000654A1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси]бензил]-тиазолидин-2,4-диона в качестве фармацевтического препарата
EA200000655A1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
ID30064A (id) Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion
EA200101101A1 (ru) Новый фармацевтический препарат
IT1206130B (it) Composti per abbassare i livelli dei lipidi.
IT1303793B1 (it) "composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico (no)"
EE03090B1 (et) Kinoliin-3-karboksamiidühendite kasutamine kompositsiooni valmistamiseks I tüüpi suhkurtõve raviks
IL77051A (en) Crystalline form of the monoethanolamine salt of n-(2-pyridyl)-2-methyl-4-hydroxy-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide and pharmaceutical compositions containing it
EP0256507A3 (en) 3-(1h-tetrazol-5-yl)oxanilic acid and salts thereof, method for preparing the same and pharmaceutical compositions containing the compound
IL67564A0 (en) (1,2)-fused 1,4-benzodiazepine compounds,their preparation and pharmaceutical compositions containing them
HUP9803041A3 (en) Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them
NZ243552A (en) 2-[2-(4-methoxy-2-pyridinyl)phenylsulphinyl]-1h-benzimidazole derivatives, preparation and pharmaceutical compositions thereof
JPS57206683A (en) Pyrimidone salt, manufacture and medicinal composition containing same
NO970477L (no) Inhibisjon av leukotrien biosyntese med ureaderivater
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy
JPS57140785A (en) Benzothiazine derivative, its preparation, and pharmaceutical composition containing the same
AU6740187A (en) Heterocyclic compounds, methods for the manufacture of the same and pharmaceutical compositions containing the same